title: Piroxicam-copper complexes: inhibition of polymorphonuclear leukocyte migration to Pseudomonas aeruginosa chemotactins in vivo and superoxide dismutase-like activity in vitro.
abstract: Piroxicam-copper (Cu2+) complexes, formed spontaneously by mixing solutions of piroxicam and CuSO4 (1:1 Cu2+:piroxicam), inhibited the superoxide anion-catalyzed reduction of ferricytochrome C in a dose-related fashion. Addition of ethylenediaminetetraacetate to the mixture decreased in a dose-related manner the superoxide dismutase (SOD)-like activity of piroxicam-Cu2+. Piroxicam alone (10(-5) M, final concentration) did not display SOD-like activity but 10(-5) M Cu2+ exhibited significant activity, similar to that of piroxicam-Cu2+. Intraperitoneal treatment of mice with either 0.64 mg/kg piroxicam or its Cu2+ complexes (0.64 mg/kg piroxicam + 0.12 mg/kg Cu2+) was equally effective in diminishing both the migration of polymorphonuclear leukocytes (PMNL) to the airways and the content of myeloperoxidase activity in the lungs, induced by aerosol challenge with Pseudomonas aeruginosa peptide chemotactins. Therefore, piroxicam-Cu2+ complexes may provide both the anti-inflammatory activity of piroxicam plus the SOD-like activity of Cu2+.
authors.affiliation: Departamento de Microbiología, Parasitología e Immunología, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
authors.forename: D O
authors.initials: DO
authors.lastname: Sordelli
authors.forename: P A
authors.initials: PA
authors.lastname: Fontán
authors.forename: C R
authors.initials: CR
authors.lastname: Amura
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D002630:Chemotactic Factors / Q000494:pharmacology*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D003300:Copper / Q000008:administration & dosage / Q000494:pharmacology*; D019327:Copper Sulfate; D003574:Cytochrome c Group / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000188:drug therapy; D004492:Edetic Acid / Q000494:pharmacology; D066298:In Vitro Techniques; D007274:Injections, Intraperitoneal; D008168:Lung / Q000166:cytology / Q000201:enzymology; D051379:Mice; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D010084:Oxidation-Reduction; D009195:Peroxidase / Q000378:metabolism; D010894:Piroxicam / Q000008:administration & dosage / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000737:chemistry; D013482:Superoxide Dismutase / Q000378:metabolism*
chemical_list: D002630:Chemotactic Factors; D003574:Cytochrome c Group; D010894:Piroxicam; D003300:Copper; D004492:Edetic Acid; D009195:Peroxidase; D013482:Superoxide Dismutase; D019327:Copper Sulfate